Abbvie’s 1.00% Drop Amid $1B Gilgamesh Talks Ranked 112th in $0.95B Trading Volume

Abbvie Inc (ABBV) saw a 1.00% decline on July 30, with a trading volume of $0.95 billion, representing a 25.79% drop from the previous day’s activity. The stock ranked 112th in terms of trading volume across the market.

Recent developments indicate Abbvie is in advanced discussions to acquire privately held Gilgamesh Pharmaceuticals for approximately $1 billion. The potential transaction, if finalized, would mark another significant acquisition for the pharmaceutical giant, which has invested over $20 billion in deals since 2023 to offset the loss of patent protection for its flagship drug Humira. Gilgamesh specializes in neuroplastogens—next-generation psychedelic compounds for psychiatric disorders such as depression, anxiety, and PTSD. The companies previously entered a licensing agreement in May, under which Gilgamesh could receive up to $1.95 billion in milestone payments.

While negotiations remain ongoing, the deal could face delays or termination. An acquisition would strengthen Abbvie’s portfolio following a setback in its schizophrenia drug development. The move aligns with growing industry interest in psychedelic therapies, with analysts projecting $4.5 billion in sector sales by 2032.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day yielded a 166.71% return from 2022 to the present, significantly outperforming the benchmark’s 29.18%. The excess return generated by this strategy is 137.53%, with a compound annual growth rate of 31.89%.